Cargando…
Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study
BACKGROUND: Glucocorticoids are the cornerstone treatment of polymyalgia rheumatica (PMR) but induce adverse events. OBJECTIVES: To evaluate the efficacy and safety of first-line tocilizumab in PMR. METHODS: In a prospective open-label study (ClinicalTrials.gov: NCT01713842), 20 glucocorticoid-free...
Autores principales: | Devauchelle-Pensec, Valérie, Berthelot, Jean Marie, Cornec, Divi, Renaudineau, Yves, Marhadour, Thierry, Jousse-Joulin, Sandrine, Querellou, Solène, Garrigues, Florent, De Bandt, Michel, Gouillou, Maelenn, Saraux, Alain |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975852/ https://www.ncbi.nlm.nih.gov/pubmed/26929219 http://dx.doi.org/10.1136/annrheumdis-2015-208742 |
Ejemplares similares
-
Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab
por: Huwart, Anaïs, et al.
Publicado: (2018) -
Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade
por: Carvajal Alegria, Guillermo, et al.
Publicado: (2021) -
Level of agreement between 2002 American–European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren’s syndrome and reasons for discrepancies
por: Cornec, Divi, et al.
Publicado: (2014) -
Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjögren’s syndrome
por: Cornec, Divi, et al.
Publicado: (2014) -
Eosinophilia predicts poor clinical outcomes in recent-onset arthritis: results from the ESPOIR cohort
por: Guellec, Dewi, et al.
Publicado: (2015)